Prognostic Factors for Progression-free Survival (PFS), Overall Survival (OS), and Long-term OS (LT-OS) With Sunitinib in 1,059 Patients, Treated on Clinical Trials, With Metastatic Renal Cell Carcinoma (mRCC)

被引：0
|
作者：
Motzer, R. J. [1 ]
Escudier, B. [2 ]
Bukowski, R. [3 ]
Rini, B. I. [3 ]
Hutson, T. E. [4 ]
Barrios, C. H. [5 ]
Lin, X. [6 ]
Fly, K. [7 ]
Matczak, E. [8 ]
Gore, M. E. [9 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Villejuif, France
[2] Inst Gustave Roussy, Immunotherapy Unit, Villejuif, France
[3] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA
[4] Baylor Sammons Canc Ctr Texas Oncol, Dallas, TX USA
[5] PUCRS Sch Med Hematol & Oncol, Porto Alegre, RS, Brazil
[6] Pfizer Oncol, Clin Stat, La Jolla, CA USA
[7] Pfizer Oncol, Oncol, New London, CT USA
[8] Pfizer Oncol, Oncol, New York, NY USA
[9] Royal Marsden Hosp NHS Trust, London, England
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)70649-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S98 / S99
页数：2
相关论文
共 50 条
  • [41] NCCTG 96-94-53: Clinical variables associated with overall survival (OS), progression-free survival (PFS), 6 month progression-free survival (PFS6), immediate progression (ImmProg), and response in patients enrolled in recurrent glioma clinical trials.
    Buckner, J. C.
    Ballman, K.
    Schaefer, P.
    Furth, A. F.
    Giannini, C.
    Scheithauer, B. W.
    Galanis, E.
    Jaeckle, K. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 63S - 63S
  • [42] Overall and progression-free survival according to MSKCC scores in 1st line sunitinib treatment of metastatic renal cell carcinoma (mRCC)
    Finek, J.
    Poprach, A.
    Melichar, B.
    Kopecky, J.
    Zemanova, M.
    Buchler, T.
    Kopeckova, K.
    Mlcoch, T.
    Dolezal, T.
    Fiala, O.
    ANNALS OF ONCOLOGY, 2019, 30 : 387 - 387
  • [43] Prognostic factors for overall survival with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)
    Patil, S.
    Figlin, R. A.
    Hutson, T. E.
    Michaelson, M. D.
    Negrier, S.
    Kim, S. T.
    Huang, X.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [44] OVERALL SURVIVAL (OS) IN METASTATIC RENAL CELL CARCINOMA (MRCC) SEQUENTIALLY TREATED WITH DIFFERENT TARGETED THERAPIES (TTS): RESULTS FROM A LARGE COHORT OF PATIENTS
    Procopio, G.
    Verzoni, E.
    Testa, I.
    Iacovelli, R.
    Garanzini, E.
    De Braud, F. G. M.
    ANNALS OF ONCOLOGY, 2012, 23 : 272 - 273
  • [45] Overall survival (OS) in metastatic renal cell carcinoma (mRCC) sequentially treated with different targeted therapies (TTs): Results from a large cohort of patients
    Procopio, Giuseppe
    Verzoni, Elena
    Iacovelli, Roberto
    Testa, Isabella
    Salvioni, Roberto
    Nicolai, Nicola
    Porcu, Luca
    De Braud, Filippo G.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [46] Quality of life (QOL) predicts for progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib compared to interferon-alpha (IFN-α)
    Cella, D.
    Li, J. Z.
    Cappelleri, J. C.
    Bushmakin, A.
    Charbonneau, C.
    Kim, S. T.
    Chen, I.
    Michaelson, M. D.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [47] Development of overall survival (OS) and progression free survival (PFS) nomograms for Australian patients with locoregionally advanced oropharyngeal squamous cell carcinoma (LA OPSCC)
    Xu, K.
    Lo, A.
    Chin, V.
    Gzell, C.
    O'Connor, C.
    Forstner, D.
    Gallagher, R.
    Bova, R.
    Crawford, J.
    Harvey, R.
    Lochhead, A.
    Earls, P.
    Qiu, M. R.
    Hsu, E.
    Bigg-Wither, G.
    Chan, L.
    Bao, H.
    Foltyn, P.
    Sim, H-W.
    Prawira, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [48] Active Smoking May Negatively Affect Response Rate, Progression-Free Survival, and Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
    Keizman, Daniel
    Gottfried, Maya
    Ish-Shalom, Maya
    Maimon, Natalie
    Peer, Avivit
    Neumann, Avivit
    Hammers, Hans
    Eisenberger, Mario A.
    Sinibaldi, Victoria
    Pili, Roberto
    Hayat, Henry
    Kovel, Svetlana
    Sella, Avishay
    Boursi, Ben
    Weitzen, Rony
    Mermershtain, Wilmosh
    Rouvinov, Keren
    Berger, Raanan
    Carducci, Michael A.
    ONCOLOGIST, 2014, 19 (01): : 51 - 60
  • [49] Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma
    Patil, S.
    Figlin, R. A.
    Hutson, T. E.
    Michaelson, M. D.
    Negrier, S.
    Kim, S. T.
    Huang, X.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2011, 22 (02) : 295 - 300
  • [50] Identifying SNPs associated with progression-free survival (PFS) and overall survival (OS) in patients with KRAS wildtype and mutant metastatic colorectal cancer (mCRC) using Random Survival Forests (RSF).
    Yang, Dongyun
    Zhang, Wu
    Cao, Shu
    Loupakis, Fotios
    Schirripa, Marta
    Stintzing, Sebastian
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345